Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.36 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 1/20 | 0.33 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074129 | 0.70 | GPR84 (0.39) | GPR84FFAR1FFAR4FAAHACACB | |
| SCHEMBL14660129 | 0.69 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL30787116 | 0.69 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL30787207 | 0.69 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL30787307 | 0.69 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL23530055 | 0.69 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL30787291 | 0.69 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL30787428 | 0.69 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL2845646 | 0.69 | GPR84 (0.46) | GPR84FFAR1FFAR4ACACBACACA | |
| SCHEMBL10822237 | 0.67 | NOD1 (0.62) | GPR84FFAR1NOD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828171-B1 | HETEROCYCLE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | ANGELETTI P IST RICHERCHE BIO (IT) | 2014-03-12 | — | — | EP | disclosed |
| US-7863294-B2 | Heterocycle derivatives as histone deacetylase (HDAC) inhibitors | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-01-04 | — | — | US | disclosed |
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | MSD ITALIA S.R.L. (IT) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048228-A1 | Heterocycle Derivatives As Histone Deacetylase (Hdac) Inhibitors | HDAC1, HDAC5, HDAC11 | GPR84 3376/4885FFAR1 3808/4885FFAR4 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.